Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control

ABSTRACT: ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control

PROVIDER: PRJNA627125 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11579386.fastq.gz	Fastqsanger.gz
	SRR11579387.fastq.gz	Fastqsanger.gz
	SRR11579388.fastq.gz	Fastqsanger.gz
	SRR11579389.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

Project description:ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

| PRJNA627126 | ENA

ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148926 | GEO

ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

Project description:ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

| PRJNA627124 | ENA

ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148925 | GEO

ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148928 | GEO

ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control

Project description:ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control

| PRJNA627123 | ENA

ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148982 | GEO

FOXA1 ChIP-seq in LNCaP cell line overexpressing WT or mutant FOXA1

Project description:FOXA1 ChIP-seq in LNCaP cell line overexpressing WT or mutant FOXA1

| PRJNA551299 | ENA

FoxA1 inhibits androgen receptor expression and suppresses prostate cancer metastasis [LNCaP, ChIP-seq]

Project description:FoxA1 has been shown critical for prostate development and prostate-specific gene expression regulation. In addition to its well-established role as an AR pioneering factor,several studies have recently revealed significant AR binding events in prostate cancer cells with FoxA1 knockdown. Furthermore, the role of FoxA1 itself in prostate cancer has not been carefully examined. Thus, it is important to understand the role of FoxA1 in prostate cancer and how it interacts with AR signaling. To address these questions, we generated LNCaP cells with stable FoxA1 knockdown. We performed AR/FoxA1 ChIP-seq and microarray analysis of these cells. ChIP_Seq examination of AR and FoxA1 binding sites in LNCaP shCtrl and shFoxA1 cells

2014-06-02 | E-GEOD-37345 | biostudies-arrayexpress

FoxA1 inhibits androgen receptor expression and suppresses prostate cancer metastasis [LNCaP, ChIP-seq]

2014-06-02 | GSE37345 | GEO